Revenue of $9.7 million in Q4 2025, up 64% year-over-year; full year revenue of $21.2 million, up 201% year-over-yearOn a pro forma basis, combined company revenue of $34.0 million for full year 2025 ...
ZYCUBOapproved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 mi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results